From July 1, 2023 to September 30, 2023, the company has repurchased 149,041 shares, representing 0.48% for $0.17 million. With this, the company has completed the repurchase of 4,708,520 shares, representing 14.3% for $15.42 million under the buyback announced on March 15, 2022.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.14 USD | 0.00% | +2.70% | -14.29% |
May. 13 | HC Wainwright Adjusts Price Target on Co-Diagnostics to $2 From $2.50, Maintains Neutral Rating | MT |
May. 09 | Transcript : Co-Diagnostics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.29% | 35.64M | |
-41.45% | 2.95B | |
+19.36% | 1.88B | |
-1.05% | 1.63B | |
+33.96% | 1.34B | |
-16.83% | 959M | |
-21.96% | 888M | |
+7.07% | 842M | |
-26.49% | 623M | |
+10.85% | 513M |
- Stock Market
- Equities
- CODX Stock
- News Co-Diagnostics, Inc.
- Tranche Update on Co-Diagnostics, Inc.'s Equity Buyback Plan announced on March 15, 2022.